Frontier Biotechnologies to Present and Update the Latest Progress of FB2001 Nebulized Aerosol Inhalation formulary at the 2022 China Pharmaceutical CMC Innovation Summit

  • 2022-12-05  09:59:48

On December 2, 2022, Dr. Min Hu, the Chief Medical Officer of Frontier Biotechnologies Inc. (the “Company”, stock code: (688221. SH) presented the latest clinical updates of COVID-19 small molecule treatment FB2001 (generic name: Bofutrelvir) for nebulized inhalation at the 2022 China Chemical Pharmaceutical CMC Innovation Summit.

Latest updates included:

1.    Data of SARS-CoV-2 Inhibitory effect: The company collaborated with Wuhan Institute of Virology, Chinese Academy of Sciences to evaluate the effect against mutant virus strains In vitro.

    FB2001 showed definite antiviral activity against Omicron BA.2 and BA.5 virus strains.

    Regarding the EC50 of the COVID-19 strains Alpha, Beta, Delta, and Omicron in Vero E6 cells, FB2001 is comparable to or better than Nirmatrelvir (Paxlovid)

2.    Phase I clinical trial of FB2001 for nebulized inhalation:

    This Phase I clinical trial was conducted in China. This study is a randomized, double-blind, placebo-parallel control with dose escalation design. Enrolled subjects were healthly men and women aged 18-60 years.

    According to the preliminary latest Phase I analysis, FB2001 nebulized aerosol formulary has a high concentration in the respiratory tract, demonstrating good clinical safety and tolerability and no dose-limiting toxicity (DLT).


Develop Innovative Therapies to Better Human Lives